Still Not At Goal with TZD

56-year-old, 5'8", 195-lb male  Type 2 diabetes diagnosed 4 years ago  Treated with pioglitazone 45 mg daily  BMI: 29.6  Fasting glucose: 110 mg/dL  2-hour postprandial glucose: 225 mg/dL  A1c: 7.4% Medical History:  Hypertension and low HDL cholesterol level

Use a medication with short duration of action, to minimize     hypoglycemia risk  Use a drug that works synergistically with TZDs

Added STARLIX 120 mg with each meal  Fasting glucose reduced to 105 mg/dL  2-hour postprandial glucose reduced to 165 mg/dL  A1c reduced to 6.7%*

Adding STARLIX to TZD therapy controlled mealtime glucose to get patient to     A1c goal * In clinical trials, when STARLIX was added to metformin there was a mean    reduction of 0.6% A1c. Individual patient responses may vary.

Important Safety Information

STARLIX is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.

STARLIX is contraindicated in patients with a known hypersensitivity to the drug or its inactive ingredients, in patients with type 1 diabetes, or in patients with diabetic ketoacidosis. Patients with ketoacidosis should be treated with insulin.

All oral blood glucose lowering drugs that are absorbed systemically are capable of producing hypoglycemia. Patients should be advised to take STARLIX 1 to 30 minutes prior to eating a meal and to skip the dose if the meal is missed.

STARLIX should be used with caution in patients with moderate to severe liver disease because such patients have not been studied.

The most common adverse events associated with STARLIX vs placebo were upper respiratory infection (10.5% vs 8.1%), back pain (4.0% vs 3.7%), flu symptoms (3.6% vs 2.6%), dizziness (3.6% vs 2.2%), arthropathy (3.3% vs 2.2%), and diarrhea (3.2% vs 3.1%).

Please see the full prescribing information.